J. Goldman & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

J. Goldman & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-39,000	Closed	-$4.77M	–	440
2016 Q4	$4.77M	Buy	+39,000	New	+$4.77M	0.32%	101

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

J. Goldman & Co's ALXN Position: Q1 2017 in Review

J. Goldman & Co sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 4,600 shares — an estimated $563K sold.

J. Goldman & Co first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $563K in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

J. Goldman & Co reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
J. Goldman & Co sold 4,600 Alexion Pharmaceuticals shares in Q1 2017, an estimated $563K.
J. Goldman & Co first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
J. Goldman & Co's Alexion Pharmaceuticals position peaked at $563K in Q4 2016.
561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on J. Goldman & Co's 13F filing for Q1 2017, filed 15 May 2017.